Auregen Biotherapeutics Announces Appointment of Scott Lauder, Ph.D., as Chief Technology Officer [Yahoo! Finance]
Disc Medicine, Inc. (IRON)
Company Research
Source: Yahoo! Finance
anatomy with cartilage cell therapy, today announced the appointment of Scott Lauder , Ph.D., as Chief Technology Officer, after initially serving in the role on an interim basis. "Scott brings deep expertise in innovative technologies and different biologic modalities, and he has a proven track record of building highly capable, fully-integrated teams. All these experiences will be invaluable as our company looks ahead to a year of important milestones," said Jason Meyenburg , Chief Executive Officer of Auregen. "Scott's unique perspective will be essential as we continue to advance the Phase 1/2 study for AUR-201, our first-in-class therapeutic ear replacement for people with microtia, and work to develop precision therapies that can replace dysfunctional tissues and restore functional anatomy." "I'm excited to join the Auregen team on a permanent basis and continue our work on the forefront of autologous tissue generation, which reduces the potential for rejection risk or donor
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Wells Fargo & Company from $91.00 to $109.00. They now have an "overweight" rating on the stock.MarketBeat
- Has Disc Medicine's 2025 Surge Already Gone Too Far After Pipeline Progress Fuels Rally? [Yahoo! Finance]Yahoo! Finance
- Disc Medicine (NASDAQ:IRON) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswire
IRON
Earnings
- 11/6/25 - Miss
IRON
Sec Filings
- 12/19/25 - Form 4
- 12/18/25 - Form 4
- 12/17/25 - Form SCHEDULE
- IRON's page on the SEC website